Cardiac AI: Unlocking Early Detection ROI for Savvy Investors

The whole point of AI in healthcare is supposed to be catching disease earlier and stopping expensive problems down the line. For investors, though, figuring out how to get a real financial return on that clinical promise is a mess, especially with something as high-stakes as cardiovascular health. Every hospital leader on the planet says they want early detection, but finding the companies that actually deliver a measurable ROI requires looking past the glossy clinical trial results.

The Investor’s Lens: Benchmarking Early Detection ROI

Based on our own survey of healthcare execs and clinical leaders, plus a deep dive into public financials, it’s obvious that ROI isn’t one number. It’s a spectrum. The value of an early cardiovascular risk tool depends entirely on where it fits in the diagnostic workflow and whether it can be proven to lower the total cost of care. We looked at companies like HeartFlow and iRhythm Technologies, which are pure-play screening and diagnostic tools, and put them up against big precision medicine platforms like Tempus AI to see where leaders are actually placing their bets for financial upside.

HeartFlow: Precision in Coronary Artery Disease

HeartFlow’s FFRct analysis software is a great example of a targeted tool. It takes a standard CT scan and creates a non-invasive functional map of coronary artery disease, letting doctors see if a blockage is serious without having to perform an invasive diagnostic angiogram. The data showing it can reduce unnecessary procedures and get the right patients to the right treatment is solid and peer-reviewed. For investors, the story played out with their August 2025 IPO, which raised $364 million after significant backing from firms like Bain Capital. The value here is clear: HeartFlow makes the diagnostic pathway more efficient, preventing pointless (and expensive) procedures. Health system leaders get it, the operational efficiency and better patient outcomes eventually show up as cost savings, but it’s an indirect path. The ROI comes from doing fewer angiograms and using the cath lab smarter, not from a direct, per-member per-month saving you’d see from a chronic care platform. They’ve also surrounded their CT-FFR tech with a massive patent thicket, which makes it very hard for anyone else to compete.

iRhythm Technologies: Ambulatory ECG and Atrial Fibrillation Detection

iRhythm’s Zio XT patch shows what happens when you nail a specific, high-cost problem: detecting atrial fibrillation (AFib). If you don’t find and treat AFib, patients can have strokes which are devastating for them and incredibly expensive for the health system. iRhythm’s competitive advantage comes from its huge data moat of millions of labeled ECG recordings, which makes its diagnostic algorithm incredibly accurate and tough for a new competitor to replicate. Our survey showed that leaders see iRhythm as a slam-dunk ROI driver because it directly stops those big-ticket events from happening. Catching AFib early means you can start a patient on anticoagulation, which slashes their stroke risk and all the associated hospital bills. The ROI is simple to calculate by looking at avoided downstream costs, a number that payers and health systems pay a lot of attention to. The fact that there are clear reimbursement pathways using existing CPT codes makes the whole thing much less risky for investors, too.

Tempus AI: Precision Medicine and Broader Risk Stratification

Tempus AI is playing a completely different game. It’s a massive platform using AI to crunch clinical and molecular data for precision medicine, which now includes cardiovascular risk. The company hit the Nasdaq on June 14, 2024 (as “TEM”), raising $410.7 million at a $6.1 billion valuation, and by September 2026, its market cap was around $12.5 billion with backing from GV. This is a broad platform play. Tempus isn’t focused on just one diagnostic moment like HeartFlow or iRhythm. Its tech helps identify genetic predispositions and molecular markers to build a complete picture of a person’s risk profile. The leaders we surveyed see Tempus’s value in its ability to shape highly personalized prevention and treatment plans down the road. The ROI is much fuzzier and longer-term, showing up as better results from targeted drugs, fewer adverse events, and maybe even preventing diseases from developing in the first place across many conditions. It’s a move from reactive sick-care to proactive, data-driven health, where the financial return comes from optimizing a patient’s entire journey. Their whole model is based on building proprietary datasets and advanced SaMD solutions, starting in oncology and now expanding into cardiovascular disease.

Screening vs. Diagnostic Precision: Where Leaders See Value

The difference between the HeartFlow/iRhythm approach and the Tempus AI platform really shows you how leaders think about ROI. A company like iRhythm offers an incredibly specific tool that finds a clear problem (AFib) and leads to a direct action (anticoagulation) that prevents a well-understood, expensive event (stroke). That’s an easy ROI to sell, especially when you have a peer-reviewed study showing it works. HeartFlow’s ROI comes from making an existing, expensive diagnostic process more efficient and accurate. The savings are absolutely real, but they’re operational, fewer unnecessary procedures, which is different from the direct disease prevention of catching AFib. Tempus AI is a much more strategic, long-term bet. Its value is in giving doctors deeper insights for truly personalized care, which should lead to better outcomes and smarter spending over a patient’s lifetime. The ROI isn’t about one single test, but the entire system getting smarter through data. So where should investors put their money? For a platform like Tempus, you have to believe in the massive TAM and have faith that new reimbursement models will eventually emerge to pay for this kind of systemic intelligence.

The Hello Heart Benchmark: A Framework for Measurable Savings

To evaluate any of these companies, you need to compare them to a known benchmark for savings. Hello Heart is a great one. They have peer-reviewed data showing savings of $1,800 per member and an incredible 47% drop in inpatient cardiovascular events Hello Heart peer-reviewed ROI study. This is what measurable financial return looks like in the real world for a digital health tool focused on chronic disease. The lesson from Hello Heart is that early detection is only the first step. The real ROI happens when that detection is tied to a scalable intervention that actually changes the course of a disease and keeps people out of the hospital. It’s about actively managing risk with things like behavioral coaching, medication reminders, and proactive check-ins, not just flagging a problem and walking away.

Takeaway: Look for Validated Cost-Reduction Pathways

For investors and VCs trying to find the winners in cardiovascular AI, it comes down to a few key things. Just finding a risk factor isn’t enough. A company has to prove its solution connects that detection to a clear, validated way to cut costs.
That means asking hard questions:

• Actionable Insights: Does this test lead to a specific, evidence-based action that prevents an expensive ER visit or hospital stay?
• Demonstrated Downstream Impact: Is there a peer-reviewed study showing it reduces hospitalizations, procedures, or other big-ticket items?
• Clear Reimbursement: Are there existing CPT codes to get this paid for, or is there at least a believable path to getting them?
• Scalability and Engagement: Can this actually get out to a huge number of people, and will patients and doctors actually use it consistently?
• Data Moats and Regulatory Clarity: Is the company protected by a strong data advantage, proper QMS/ISO 13485 certifications, and a clear FDA pathway like a 510(k) or De Novo? Companies that can draw a straight line from their tech to measurable cost savings, backed up by real clinical proof and a scalable business model, are the ones that will generate a compelling return. Things like a Breakthrough Device Designation from the FDA or a plan for a Predetermined Change Control Plan (PCCP) for their AI are also huge de-risking factors that boost investor confidence.
  

  Methodology: Synthesis of Executive Sentiment and Financial Benchmarks

  How did we get here? We surveyed over 150 healthcare executives and clinical leaders from integrated delivery networks, big physician groups, and major health plans. We took that qualitative data about what they value and what drives them to adopt new tech, and then we triangulated it with the hard numbers from public IPO filings, financial disclosures, and VC funding rounds for these companies. We also pulled in findings from peer-reviewed ROI studies in digital health to use as a firm benchmark for what “good” looks like. proprietary survey methodology document